

S

*click [HERE](#) for an explanation of standardised wording to be used by Scottish Boards regarding decisions on medicines since May 2016 [Link to Formulary](#)

Medicine	Indication	NHS Board Decision*	DTC Supplement	Date
Sacituzumab govitecan 180mg powder for concentrate for solution for infusion (Trodelvy®) SMC2446	Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease.	Available in line with national guidance	188	April 2022
Sacubitril/valsartan 24mg/26mg, 49mg/51mg and 97mg/103mg film-coated tablets (Entresto®) 1132/16	In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction	Available in line with national guidance GP under direction of secondary care	154	May 2016
Safinamide, 50mg/100mg film-coated tablets (Xadago®) SMC No. (1259/17)	Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients	Not available as not recommended for use in NHS Scotland	162	Aug 2017
Salbutamol sulphate (Salbulin MDPI Novoliser®)	Asthma		83	Oct 2008
Salmeterol/fluticasone 50/500mcg inhaler (Serevent 500 Accuhaler®)	COPD		86 77	Jan 2009 Mar 2008
Salmeterol 25mcg inhaler (Serevent Evohaler®)	Asthma		60	2006
Sapropterin dihydrochloride, 100mg, soluble tablets (Kuvan®) SMC No 558/09	The treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.	Not available as not recommended for use in NHS Scotland	170	Sep 2018

Sapropterin (Kuvan®)	Hyperphenylalaninaemia (HPA)		90	June 2009
Sarilumab 150mg and 200mg solution for injection in pre-filled syringe and pre-filled pen (Kevzara®) SMC No 1314/18	In combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Sarilumab can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. SMC restriction: in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs. In patients with severe disease inadequately controlled by a TNF antagonist, it may be used in patients ineligible to receive rituximab.	Not routinely available as local implementation plans are currently being developed or the ADTC is waiting for further advice from local clinical expert	168	May 2018
Satralizumab solution for injection in pre-filled syringe (Enspryng) Roche Products Ltd SMC2663	As a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.		Awaiting publication	April 2024
Saxagliptin 5mg/dapagliflozin 10mg film-coated tablets (Qtern®) SMC No (1255/17)	In adults aged 18 years and older with type 2 diabetes mellitus: <ul style="list-style-type: none"> • to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern® do not provide adequate glycaemic control, • when already being treated with the free combination of dapagliflozin and saxagliptin SMC Restriction: for use in combination with metformin when the use of a sulphonylurea is inappropriate.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	163	Sep 2017
Saxagliptin (Onglyza®) (958/14)	Type 2 diabetes mellitus	Not recommended	136	Mar/Apr 2014
Saxagliptin (Komboglyze®) (929/13)	An adjunct to diet and exercise to improve glycaemic control	Formulary	134	Jan/Feb 2014

Saxagliptin (Onglyza®) (918/13)	Adult patients aged 18 years and older with type 2 diabetes mellitus	Formulary	133	Dec 13/Jan 14
Saxagliptin plus metformin (Komboglyze®) (870/13)	Adjunct to diet and exercise to improve glycaemic control	Formulary	128	June/July 2013
Saxagliptin (Onglyza®) (772/12)	Type 2 diabetes mellitus	Non-formulary - absence of clinician demand	143 115 98 Further info 96 95	Nov/Dec 2014 Mar/Apr 2012 Aug/Sept 2010 Apr/May 2010 Feb/Mar 2010
sebelipase alfa 2mg/mL concentrate solution (Kanuma®) SMC2437		Not available as not recommended for use in NHS Scotland	188	April 2022
Secukinumab 150mg solution for injection in pre-filled syringe and 150mg solution for injection in pre-filled pen (Cosentyx®) SMC2308	Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs. In a randomised phase III study, secukinumab, compared with placebo, significantly improved symptoms in adults with active non-radiographic axial spondyloarthritis.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	183	March 2021
Secukinumab 150mg prefilled syringe, 150mg pre-filled pen (Cosentyx®)	Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying antirheumatic drug (DMARD) therapy has been inadequate	Available in line with national guidance	156	Sep 2016
Secukinumab	Treatment of active ankylosing spondylitis (AS) in adults who	Available in line with national	156	Sep 2016

(Cosentyx®)1159/16	have responded inadequately to conventional therapy.	guidance Hospital Only (Rheumatology Clinic)		
Secukinumab (Cosentyx®) (1054/15)	For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Hospital Only Dermatology Clinic Dermatology Specialist List	149	Jun/Jul 2015
Secukinumab 150 mg or 300 mg solution for injection in pre-filled pen or pre-filled syringe (Cosentyx®) SMC2592	For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected May 2024.	197 – Awaiting publication	Apr 2024
Selexipag, 200, 400, 600, 800, 1,000, 1,200, 1,400 & 1,600 microgram film-coated tablets (Uptravi®) SMC No. (1235/17)	For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies. SMC Restriction: combination therapy in a sub-population of patients with PAH specifically those in WHO FC III who are insufficiently controlled with an ERA and a PDE-5 inhibitor and who would be considered for treatment with inhaled iloprost.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts- decision expected by September 2018	163 169	Sep 2017 July 2018
Selpercatinib hard capsules (Retsevmo®) SMC2573	Monotherapy for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. SMC restriction: for use in treatment-naïve patients who have not previously received a RET-inhibitor or any other	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for	195	December 2023

	systemic treatments for their advanced stage of disease.	alternative medicines.		
Selpercatinib 40mg and 80mg hard capsules (Retsevmo®) SMC2371		Not available as not recommended for use in NHS Scotland	188	April 2022
Selpercatinib, 40mg and 80mg hard capsules (Retsevmo®) SMC2370	<p>Selpercatinib as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib.</p> <p>Selpercatinib as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.</p> <p>In a phase I/II study, in previously treated patients with RET-fusion positive thyroid cancer or RET-mutant MTC, selpercatinib was associated with an objective response rate of 79% and 69% respectively.</p> <p>This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.</p>	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines	187	Dec 2021
Selumetinib hard capsules (Koselugo®) SMC2540	As monotherapy for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above.	Not available as not recommended for use in NHS Scotland	194	September 2023
Semaglutide, 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg FlexTouch solution for injection in pre-filled pen (Wegovy®) SMC2497	<p>As an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of</p> <ul style="list-style-type: none"> • $\geq 30\text{kg/m}^2$ (obesity), or • $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity. 	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	195	December 2023

	<p>SMC restriction: BMI of $\geq 30\text{kg/m}^2$* in the presence of at least one weight-related comorbidity. Patients should be treated in a specialist weight management service.</p> <p>*a lower BMI cut-off may be more appropriate for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p>			
<p>Semaglutide 3mg, 7mg and 14mg tablets (Rybelsus®) SMC2287</p>	<p>For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise</p> <ul style="list-style-type: none"> • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications • In combination with other medicinal products for the treatment of diabetes. <p>SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option.</p> <p>SMC has previously accepted semaglutide solution for subcutaneous injection (Ozempic®) for restricted use (SMC2092). Oral semaglutide (Rybelsus®) costs the same per day as subcutaneous semaglutide (Ozempic®). Prescribers should note that the effect of switching between oral and subcutaneous semaglutide cannot easily be predicted because of high pharmacokinetic variability of oral semaglutide. Clinical effectiveness should be considered when making switching decisions between formulations</p>	<p>Available in line with local guidance for prescribing</p>	<p>181</p>	<p>November 2020</p>
<p>Semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic®) SMC2092</p>	<p>The treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise:</p> <ul style="list-style-type: none"> • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications • In addition to other medicinal products for the treatment of 	<p>Available in line with local guidance for prescribing</p>	<p>173</p>	<p>March 2019</p>

	diabetes. SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option			
Sertraline (Lustral®)	Post-traumatic stress disorder in females		33	2003
Setmelanotide 10mg/ml solution for injection (Imcivree®) SMC2565	Treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.	Not available as not recommended for use in NHS Scotland		
Setmelanotide (Imcivree®) SMC2647	Treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) in adults and children 6 years of age and above.		196- Awaiting publication	Feb 2024
Sevelamer (Renagel®)	Hyperphosphataemia in adult patients receiving peritoneal dialysis		75	Dec 2007
sevelamer carbonate 2.4g powder for oral suspension (Renvela®) SMC No 1304/18	Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m ²) with chronic kidney disease. SMC restriction: the second-line management of hyperphosphataemia in patients receiving haemodialysis.	Available in line with national guidance	167	April 2018
Sevelamer carbonate (Renvela®) (641/10)	Hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis	GPs may prescribe under the direction of the Renal Clinic	105 100	April/May 2011 Oct/Nov 2010
Sildenafil (Revatio®) (809/12)	Patients aged 1 year to 17 years old with pulmonary arterial hypertension.	GPs may prescribe under the direction of a tertiary centre.	123	Jan 2013

Sildenafil (Revatio®) (688/11)	Pulmonary arterial hypertension	HOSPITAL ONLY (Under the direction of the Scottish Pulmonary Vascular Unit or the Scottish Adult Congenital Cardiac Service)	104	Mar 2011
Sildenafil (Revatio®) (596/10)	Patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II, to improve exercise capacity.	Restricted to initiation and supply by specialists working in the Scottish Pulmonary Vascular Centres	95	Feb/Mar 2010
Sildenafil (Revatio®) (235/06)	Pulmonary arterial hypertension	Restricted to the Scottish Pulmonary Vascular Unit	56	2006
Simeprevir (Olysio®) (988/14)	Chronic hepatitis C in adults	HOSPITAL ONLY (Hepatitis Team)	141	Sept/Oct 2014
Siponimod 250 microgram and 2mg film-coated tablets (Mayzent®) SMC2265	Treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. In a randomised, double-blind, placebo-controlled phase III study, siponimod was associated with a reduction in disability progression confirmed after 3 months in patients with SPMS.	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by January 2021	181	November 2020
Sirolimus 0.5mg, 1mg and 2mg coated tablets and 1mg/ml oral solution (Rapamune®) SMC2126	Treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function	Not available as not recommended for use in NHS Scotland	172	Dec 2018
Sitagliptin plus metformin (Januvia®)	Adjunct to diet and exercise		99	Aug/Sept 2010
Sitagliptin (Janumet®)	Adjunct to improve glycaemic control with Type 2 diabetes		98 Further info 97	June/Jul 2010
Sitagliptin (Januvia®)	Type 2 diabetes in combination with metformin		98 Further	Aug/Sept

			info 97 96 83 73	2010 June/Jul 2010 Apr/May 2010 Oct 2008 Oct 2007
Sitagliptin (Januvia®) (108315)	For the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Formulary - GPs may prescribe under direction of the Diabetes team.	151	Sep/Oct 2015
Sitaxentan (Thelin®)	Pulmonary arterial hypertension		68	May 2007
Sodium Oxybate (Xyrem®)	Cataplexy with narcolepsy		72 57	Sept 2007 2006
Sodium phenylbutyrate (Pheburane®) (914/13)	Adjunctive therapy in the chronic management of urea cycle disorders	GP under the direction of the Metabolic Disorder Clinic	132	Nov/Dec 2013
Sodium zirconium cyclosilicate 10g powder for oral suspension (Lokelma®) SMC2515	For the treatment of hyperkalaemia in adult patients SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care. Sodium zirconium cyclosilicate offers an additional treatment choice in the therapeutic class of non-absorbed cation-exchange compounds that act as selective potassium binders.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	191	Nov 2022
Sodium zirconium cyclosilicate 5g and 10g powder for oral suspension (Lokelma®) SMC2288	Treatment of hyperkalaemia in adult patients. SMC restriction: patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a	Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts, decision expected by	181	November 2020

	clinically acceptable serum potassium level (normokalaemia) Sodium zirconium cyclosilicate, compared with placebo, reduced serum potassium in two and four-week studies in adults with hyperkalaemia. In an uncontrolled one-year study sodium zirconium cyclosilicate produced normal serum potassium in a proportion of adults with hyperkalaemia	January 2021		
Sodium zirconium cyclosilicate 5g and 10g powder for oral suspension (Lokelma®) SMC2233	Treatment of hyperkalaemia in adult patients. Sodium zirconium cyclosilicate, compared with placebo, reduced serum potassium in two and four-week studies in adults with hyperkalaemia. In an uncontrolled one-year study sodium zirconium cyclosilicate produced normal serum potassium in a proportion of adults with hyperkalaemia. The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.		179	Apr 2020
Sofosbuvir 400mg film-coated tablets (Sovaldi ®) SMC No 1326/18	In combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to <18 years.	Not available as not recommended in NHS Scotland	168	May 2018
Sofosbuvir 400mg, velpatasvir 100mg, voxilaprevir 100mg film-coated tablet (Vosevi®) SMC No 1317/18	Treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: for patients who: (1) Have failed to achieve a sustained virologic response (SVR) with a direct-acting anti-viral (DAA) or (2) are DAA-naïve, have genotype 3 (GT3) HCV infection, with or without cirrhosis, and are suitable for treatment with an eight-week course.	Available in line with National Guidance	168	May 2018
Sofosbuvir 400mg, velpatasvir 100mg film-coated tablets (Epclusa®) SMC No (1271/17)	Treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: in patients with genotype 1 or 4 HCV infection.	Available in line with national guidance	164 168	Nov 2017 May 2018
Sofosbuvir 400mg, velpatasvir 100mg film-coated tablets	Treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: in patients with genotype 3 (GT3) chronic HCV	Available in line with national guidance	158	Dec 2016

(Eplclusa®) SMC 1195/16	infection.			
Sofosbuvir (Sovaldi®) (964/14)	Chronic hepatitis C (CHC) in adults	HOSPITAL ONLY (Hepatitis Team)	139	June/July 2014
Solifenacin succinate plus tamsulosin hydrochloride (Vesomni®) (945/14)	For the treatment of moderate to severe storage symptoms associated with benign prostatic hyperplasia in men	Non-formulary - absence of clinician demand	136	Mar/Apr 2014
Solifenacin (Vesicare®)	Urge incontinence	Formulary	94 55 54 46	Dec 09/Jan 10 2005 2005 2004
Solriamfetol 75mg and 150mg film-coated tablets (Sunosi®) SMC2439	SMC restriction: for use in patients who have failed modafinil or have a contraindication or intolerance to modafinil. Indication under review: to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy). Solriamfetol, compared with placebo, reduced excessive daytime sleepiness in adults with narcolepsy.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
solriamfetol 75mg and 150mg film-coated tablets (Sunosi®) SMC2419	To improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).	Not available as not recommended for use in NHS Scotland	188	April 2022
Somatropin (Saizen®) (737/11)	See summary SMC Advice for details of indications	GPs may prescribe under the direction of Adult or Paediatric Endocrinology Clinic	112	Dec 2011
Somatropin (Omnitrope®)	See SMC summary advice for details of indications	GPs may prescribe under the direction of Adult or Paediatric Endocrinology Clinic	95	Feb/Mar 2010

Somatropin (Genotropin®)	Short children born small for gestational age (SGA)		59 56	2006
Somatropin (Norditropin SimpleXx®)	Short children born small for gestational age (SGA)		59	2006
Somatrogon 24mg and 60mg solution for injection in pre-filled pen (Ngenla®) SMC2493	For the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone Somatrogon offers an additional treatment choice in the therapeutic class of recombinant human growth hormones for this indication.	Not routinely available as local clinical experts do not wish to add the medicine to the formulary at this time or there is a local preference for alternative medicines.	190	August 2022
Sorafenib 200mg film-coated tablets (Nexavar®) SMC No. (1055/15)	For the treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.	Non-Formulary pending specialist decision	150	June 2015
Sorafenib (Nexavar®) (482/08)	The treatment of hepatocellular carcinoma. SMC Restriction: in patients with advanced hepatocellular carcinoma who have failed or are unsuitable for surgical or loco-regional therapies.	Non-Formulary Pending local Agreement	102 81 153	Jan/Feb 2011 July 2008 Jan/Feb 2016
Sorafenib (Nexavar®)	Advanced renal cell carcinoma		63	2006
sotorasib 120mg film-coated tablets (Lumykras®) SMC2443	As monotherapy for the treatment of adult patients with KRAS G12C-mutated, locally advanced or metastatic, non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to platinum-based chemotherapy and/or anti PD-	Available in line with national guidance	188	April 2022

	1/PD-L1 immunotherapy.			
standardised allergen extract of pollen from white birch betula verrucosa oral lyophilisate (Itulazax 12 SQ-Bet®) SMC2471	In adult patients for the treatment of moderate-to-severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch homologous group. ITULAZAX is indicated in patients with a clinical history of symptoms despite use of symptom-relieving medication and a positive test of sensitisation to a member of the birch homologous group (skin prick test and/or specific IgE).	Not available as not recommended for use in NHS Scotland	188	April 2022
Stiripentol 250mg and 500mg hard capsule, 250mg and 500mg powder for oral suspension in sachet (Diacomit®) SMC No. (524/08)	In conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.	Available in line with national guidance	86 164	Jan 2009 Oct 2017
Strontium ranelate (Protelos®) (816/12) - Removed	Osteoporosis in men at increased risk of fracture	Removed from formulary	138 (update) 128 (update) 121	May/June 2014 June/July 2013 Nov 2012
Strontium ranelate (Protelos®) - Removed	Postmenopausal osteoporosis	Removed from formulary	138 (update) 75 55 53	May/June 2014 Dec 2007 Feb 2006 2005
Sucroferric oxyhydroxide (Velphoro®) (1035/15)	For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).	Non formulary - absence of clinician demand	147	Apr 2015
Sufentanil citrate 15 micrograms sublingual tablets (Zalviso®) (1270/17)	Management of acute moderate to severe post-operative pain in adult patients.	Not available as not recommended for use in NHS Scotland	163	Sep 2017
Sugammadex (Bridion®)	Immediate reversal of rocuronium-induced neuromuscular	HOSPITAL ONLY	126 Policy	Apr 2013

(527/09)	blockade	(Anaesthetics)	104 86	Mar/Apr 2011 Jan 2009
Sumatriptan (Imigran Radis®)	Migraine		47 45	2004
Sunitinib (Sutent®) (698/11)	Pancreatic neuroendocrine tumours	HOSPITAL ONLY (Oncology)	116 106	Apr/May 2012 May/June 2011
Sunitinib (Sutent®) (698/11)	Gastrointestinal stromal tumour (GIST)	HOSPITAL ONLY (Oncology)	108 Protocol 93 62	Aug 2011 Oct/Nov 2009 2006
Sunitinib (Sutent®)	Advanced and/or metastatic renal cell carcinoma		88 71 66	Apr 2009 June 2007 Feb 2007

Updated: 15th March 2024

[Back to top](#)

[Back to homepage](#)